First to market is only part of the equation. Not the be all and end all. Which was the argument you made that I addressed.
I'm well aware of the superiority of semaglutide vs exenatide. It's not a 'Me-too'. Yet both are still GLP1 agonists. Both have the same MOA. Both control blood glucose and lower weight. They're not different in that respect.
Are you trying to suggest that Azer Cell will be a 'Me-too'?
Exenatide was a flop, for many reasons I can't be arsed to detail. Even though, at the time, it was excellent compared to what was available for relevant patients. The marketing was poor, and the market wasn't ready.
Until you work in BP. I don't think you'll understand. You can show as many PDF's as you like.
You're just a simple allied health professional with lots of opinions, and time it appears. Your job title is for preventative medicine.
Pharmaceuticals (prescribing or marketing) aren't your forte.
Stay in your lane.
IMU Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)